|
Jul 25
|
Metastatic Hormone Refractory Prostate Cancer Pipeline Market Research Report 2025 | In-depth Analysis of 180+ Companies and Over 200 Drugs in Development
|
|
Jul 25
|
Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC
|
|
Jul 25
|
Apple, Amazon, Meta Highlight Earnings Calendar; S&P 500 Titan Sets Up Ahead Of Results
|
|
Jul 25
|
Saudi Arabia IVF Market Outlook Report 2025-2033 | Rising Infertility, Medical Advances, Government Supports and Societal Shifts Driving Growth
|
|
Jul 25
|
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
|
|
Jul 25
|
U.S. Keytruda Market Research Report 2025 | Merck's Keytruda Faces Challenges as Patent Expiry Approaches in 2028 - Forecast to 2033
|
|
Jul 25
|
Post-Operative Nausea and Vomiting Market Report 2025: Surge in Surgical Procedures Fuels $2.97 Billion Growth in PONV Market by 2029
|
|
Jul 25
|
UBS Bullish on Merck (MRK) Following Verona Pharma Purchase
|
|
Jul 24
|
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
|
|
Jul 24
|
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
|
|
Jul 24
|
Fibroblast Growth Factors (FGFs) Global Market Report 2025-2029 & 2034 | Regenerative Medicine Demand and Biotech Advancements Fueling Expansion
|
|
Jul 24
|
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
|
|
Jul 24
|
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
|
Jul 24
|
Exploring Analyst Estimates for Merck (MRK) Q2 Earnings, Beyond Revenue and EPS
|
|
Jul 24
|
Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends in DLBCL
|
|
Jul 24
|
Looking For Yields: Merck, Hormel Foods, And Spire Are Consistent Moneymakers
|
|
Jul 24
|
Mountain Valley MD Holdings Announces Changes to Board of Directors
|
|
Jul 23
|
Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results
|
|
Jul 23
|
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
|
|
Jul 2
|
Merck's HPV Vaccine Gardasil Remains Key Driver Ahead of Q2 Results, UBS Says
|